Hence, EGFR activating mutations are predictive biomarkers of high RR and prolonged PFS for EGFR tyrosine kinase inhibitor (TKI) therapy in NSCLC [22, 23, 25, 28–30]. Here, EGFR is linked to non-small cell lung carcinoma.